The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients

Clinical studies in patients with newly diagnosed glioblastoma treated with temozolomide have shown that the methylation status of the O(6)-methylguanine-DNA methyltransferase (MGMT) gene is both predictive and prognostic of outcome. Methylation of the promoter region of MGMT is the most clinically relevant measure of MGMT expression and its assessment has become integral in current and planned clinical trials in glioblastoma. Our study confirmed that MGMT methylation, assessed by pyrosequencing, is associated with a significant survival benefit in glioblastoma patients treated with temozolomide (either concurrently with radiotherapy or sequential treatment). More interestingly, our study demonstrated that a promoter variant, the c.-56C>T (rs16906252) single nucleotide polymorphism (SNP) located within a cis-acting enhancer element at the proximal end of MGMT, is associated with the presence of MGMT promoter methylation in de novo glioblastoma. Furthermore, we show that the overall survival of patients carrying both the SNP and MGMT methylation showed a strong survival benefit when compared to either molecular event on their own. Promoter reporter experiments in MGMT methylated glioblastoma cell lines showed the T allele conferred a ∼30% reduction in normalised MGMT promoter activity compared to the wild-type haplotype. This might account for the propensity of the T allele to undergo promoter methylation, and in turn, the improved survival observed in carriers of the T allele. An independent validation on larger cohorts is required to confirm the prognostic and predictive value of individuals carrying the T allele.

O030 Evasion of the OAS-RNase L pathway by murine coronavirus ns2 protein is required for viral replication and hepatitis

Introduction

The 2′,5′-oligoadenylate synthetase-ribonuclease L (OAS-RNase L) system is a potent IFN induced antiviral pathway. Following infection, IFNs induce a group of OAS genes whose products are activated by viral double-stranded RNA. OAS uses ATP to generate 2′,5′-linked oligoadenylates (2-5A). 2-5A binds to and activates the ubiquitous cellular endoribonuclease RNase L causing cleavages of single stranded regions of both viral and cellular RNA thus inhibiting viral replication. In addition, detection of the newly generated short RNAs by cellular pattern recognition receptors, MDA5 and RIG-I, further enhances IFN production and the ensuing antiviral activities. The intracellular concentration of 2-5A is believed to be the primary factor controlling RNase L activation. The liver contains abundant innate immune cells, which provide the first line of defense against pathogens. However, the factors that determine whether a virus can bypass this defense to access and infect the liver parenchyma are not well understood. The murine coronavirus, mouse hepatitis virus (MHV), strain A59, infection of mice provides a model for virus induced hepatitis. The MHV accessory protein, ns2, antagonizes the type I IFN response in macrophages and promotes the induction of hepatitis. Here we will describe how the ns2 protein facilitates the development of viral hepatitis by blocking OAS-RNase L pathway.

Methods

Bone marrow macrophages (BMM) from wild type (wt) and RNase L−/− mice were infected with A59 and ns2 mutant MHV. Viral titers were determined by plaque assays. RNase L activity was monitored by rRNA integrity in RNA chips. Intracellular levels of 2-5A were measured using RNase L activation assays. Effects of ns2 on 2-5A levels in cells were determined by transfecting ns2 or mutant ns2 cDNAs into HEK-293T cells. Recombinant ns2 and mutant ns2H126R proteins were purified and incubated with 2-5A in vitro and the 2-5A breakdown products were measured by HPLC. Hepatitis was determined by histology following inoculation A59 or ns2 mutant MHV into wt and RNase L−/− mice.

Results

We found evidence for a new molecular mechanism of subversion of the RNase L pathway in macrophages that regulates acute hepatitis during MHV infection. Coronavirus ns2 belongs to the LigT-like protein family, within the 2H phosphoesterase superfamily, some of which possess cyclophosphodiesterase activity (CPD). We have found that ns2 is not a CPD, but instead is a 2′,5′-phosphodiesterase (PDE) that cleaves, and thus eliminates 2-5A, the activator of RNase L. We observed that ns2 blocks the IFN inducible OAS-RNase L pathway to facilitate hepatitis development. Ns2 prevents activation of RNase L and consequently limits viral RNA degradation. An ns2 mutant virus was unable to replicate in the liver or induce hepatitis in wt mice, but was highly pathogenic in RNase L−/− mice. Thus, RNase L is a critical cellular factor for protection against viral infection of the liver and the resulting hepatitis.

Conclusion

MHV accessory protein ns2 is a 2′,5′-PDE which degrades 2-5A and limits RNase L activation thus facilitating virus-induced hepatitis in mice.

HLA-DQ association and allele competition in Chinese narcolepsy

In Japanese, Koreans and Caucasians, narcolepsy/hypocretin deficiency is tightly associated with the DRB1*15:01-DQA1*01:02-DQB1*06:02 haplotype. Studies in African-Americans suggest a primary effect of DQB1*06:02, but this observation has been difficult to confirm in other populations because of high linkage disequilibrium between DRB1*15:01/3 and DQB1*06:02 in most populations. In this study, we studied human leucocyte antigen (HLA) class II in 202 Chinese narcolepsy patients (11% from South China) and found all patients to be DQB1*06:02 positive. Comparing cases with 103 unselected controls, and 110 and 79 controls selected for the presence of DQB1*06:02 and DRB1*15:01, we found that the presence of DQB1*06:02 and not DRB1*15:01 was associated with narcolepsy. In particular, Southern Chinese haplotypes such as the DRB1*15:01-DQA1*01:02-DQB1*06:01 and DRB1*15:01-DQA1*01:02-DQB1*05 were not associated with narcolepsy. As reported in Japanese, Koreans, African-Americans and Caucasians, additional protective effects of DQA1*01 (non-DQA1*01:02) and susceptibility effects of DQB1*03:01 were observed. These results illustrate the extraordinary conservation of HLA class II effects in narcolepsy across populations and show that DRB1*15:01 has no effect on narcolepsy susceptibility in the absence of DQB1*06:02. The results are also in line with a previously proposed 'HLA-DQ allelic competition model' that involves competition between non-DQA1*01:02, non-DQB1*06:02 'competent' (able to dimerize together) DQ1 alleles and the major DQα*01:02/ DQβ*06:02 narcolepsy heterodimer to reduce susceptibility.

Denis RD, Stahlman J, Stamen R, Stanecka E, Stanek RW, Stanescu C, Stanescu-Bellu M, Stapnes S, Starchenko EA, Stark J, Staroba P, Starovoitov P, Staszewski R, Staude A, Stavina P, Steele G, Steinbach P, Steinberg P, Stekl I, Stelzer B, Stelzer HJ, Stelzer-Chilton O, Stenzel H, Stern S, Stewart GA, Stillings JA, Stockton MC, Stoerig K, Stoicea G, Stonjek S, Strachota P, Stradling AR, Straessner A, Strandberg J, Strandberg S, Strandlie A, Strang M, Strauss E, Strauss M, Strizenec P, Ströhmer R, Strom DM, Strong JA, Stroynowski R, Strube J, Stugu B, Stumer I, Stupak J, Sturm P, Styles NA, Soh DA, Su D, Subramania HS, Succurro A, Sugaya Y, Suhr C, Suk M, Sulin VV, Sultansoy S, Sumida T, Sun X, Sundermann JE, Suruliz K, Susinno G, Sutton MR, Suzuki Y, Suzuki Y, Svatos M, Swedish S, Sykora I, Sykora T, Sánchez J, Ta D, Tackmann K, Taffard A, Tafirout R, Taiblum N, Takahashi Y, Takai H, Takashima R, Takeda H, Takeshita T, Takubo Y, Talby M, Talyshev A, Tamsett MC, Tanaka J, Tanaka R, Tanaka S, Tanaka S, Tanasijczuk AJ, Tani K, Tannoury N, Tapprogge S, Tardif D, Tarem S, Tarrade F, Tartarelli GF, Tas P, Tasevsky M, Tassi E, Tatarkhanov M, Tayalati Y, Taylor C, Taylor FE, Taylor GN, Taylor W, Teinturier M, Teixeira Dias Castanheira M, Teixeira-Dias P, Temming KK, Ten Kate H, Teng PK, Terada S, Terashi K, Terron J, Testa M, Teuscher RJ, Therhaag J, Theveneaux-Pelzer T, Thoma S, Thomas JP, Thompson EN, Thompson PD, Thompson PD, Thompson AS, Thomsen LA, Thomson E, Thomson M, Thun RP, Tian F, Tibbetts MJ, Tic T, Tikhomirov VO, Tikhonov YA, Timoshenko S, Tipton P, Tique Aires Viegas FJ, Tisserant S, Todorov T, Todorova-Nova S, Toggerson B, Tojo J, Tokár S, Tokushuku K, Tollefson K, Tomoto M, Tompkins L, Toms K, Tonoyan A, Topfel C, Topilin ND, Torchiani I, Torrence E, Torres H, Torró Pastor E, Toth J, Touchard F, Tovey DR, Trefzger T, Tremblet L, Tricoli A, Trigger IM, Trincaz-Duvoid S, Tripiana MF, Trischuk W, Trocmé B, Troncon C, Trottier-McDonald M, Trzebinski M, Trzupek A, Tsarouchas C, Tseng JCL, Tsiakiris M, Tsiareshka PV, Tsionou D, Tsipolitis G, Tsiskaridze V, Tskhadadze EG, Tsukerman II, Tsulaia V, Tsung JW, Tsuno S, Tsybychev D, Tua A, Tudorache A, Tudorache V, Tuggle JM, Turala M, Turecek D, Turk Cakir I, Turlay E, Turra R, Tuts PM, Tykhonov A, Tylmad M, Tyndel M, Tzanakos G, Uchida K, Ueda I, Ueno R, Ugland M, Uhlenbrock M, Uhrmacher M, Ukegawa F, Unal G, Undrus A, Unel G, Unno Y, Urbaniec D, Usai G, Uslenghi M, Vacavant L, Vacek V, Vachon B, Vahsen S, Valenta J, Valente P, Valentinetti S, Valero A, Valkar S, Valladolid Gallego E, Vallecorsa S, Valls Ferrer JA, van der Graaf H, van der Kraaij E, Van Der Leeuw R, van der Poel E, van der Ster D, van Eldik N, van Gemmeren P, van Vulpen I, Vanadia M, Vandelli W, Vaniachine A, Vankov P, Vannucci F, Vari R, Varol T, Varouchas D, Vartapetian A, Varvell KE, Vassilakopoulos VI, Vazeille F, Vazquez Schroeder T, Vegni G, Veillet JJ, Veloso F, Veness R, Veneziano S, Ventura A, Ventura D, Venturi M, Venturi N, Vercesi V, Verducci M, Verkerke W, Vermeulen JC, Vest A, Vetterli MC, Vichou I, Vickey T, Vickey Boeriu OE, Viehhauser GHA, Viel S, Villa M, Villaplana Perez M, Vilucchi E, Vincter MG, Vinek E, Vinogradov VB, Virchaux M, Virzi J, Vitells O, Viti M, Vivarelli I, Vives Vaque F, Vlachos S, Vladoiu D, Vlasak M, Vogel A, Vokac P, Volpi G, Volpi M, Volpini G, von der Schmitt H, von Loeben J, von Radziewski H, von Toerne E, Vorobel V, Vorwerk V, Vos M, Voss R, Voss TT, Vossebeld JH, Vranjes N, Vranjes Milosavljevic M, Vrba V, Vreeswijk M, Vu Anh T, Vuillermet R, Vukotic I, Wagner W, Wagner P, Wahlen H, Wahrmund S, Wakabayashi J, Walch S, Walder J, Walker R, Walkowiak W, Wall R, Waller P, Wang C, Wang H, Wang H, Wang J, Wang J, Wang R, Wang SM, Wang T, Warburton A, Ward CP, Warsinsky M, Washbrook A, Wasicki C, Watkins PM, Watson AT, Watson IJ, Watson MF, Watts G, Watts S, Waugh AT, Waugh BM, Weber M, Weber MS, Weber P, Weidberg AR, Weigell P, Weingarten J, Weiser C, Wellenstein H, Wells PS, Wenaus T, Wendland D, Weng Z, Wengler T, Wenig S, Wermes N, Werner M, Werner P, Werth M, Wessels M, Wetter J, Weydert C, Whalen K, Wheeler-Ellis SJ, White A, White MJ, White S, Whitehead SR, Whiteson D, Whittington D, Wicek F, Wicke D, Wickens FJ, Wiedenmann W, Wielers M, Wienemann P, Wiglesworth C, Wiik-Fuchs LAM, Wijeratne PA, Wildauer A, Wildt MA, Wilhelm I, Wilkens HG, Will JZ, Williams E, Williams HH, Willis W, Willocq S, Wilson JA, Wilson MG, Wilson A, Wingerter-Seez I, Winkelmann S, Winklmeier F, Wittgen M, Wollstadt SJ, Wolter MW, Wolters H, Wong WC, Wooden G, Wosiek BK, Wotschack J, Woudstra MJ, Wozniak KW, Wraight K, Wright C, Wright M, Wrona B, Wu SL, Wu X, Wu Y, Wulf E, Wynne BM, Xella S, Xiao M, Xie S, Xu C, Xu D, Yabsley B, Yacoob S, Yamada M, Yamaguchi H, Yamamoto A, Yamamoto K, Yamamoto S, Yamamura T, Yamanaka T, Yamaoka J, Yamazaki T, Yamazaki Y, Yan Z, Yang H, Yang UK, Yang Y, Yang Z, Yanush S, Yao L, Yao Y, Yasu Y, Ybeles Smit GV, Ye J, Ye S, Yilmaz M, Yoosoofmiya R, Yorita K, Yoshida R, Young C, Young CJ, Youssef S, Yu D, Yu J, Yu J, Yuan L, Yurkewicz A, Zabinski B, Zaidan R, Zaitsev AM, Zajacova Z, Zanello L, Zaytsev A, Zeitnitz C, Zeman M, Zemla A, Zendler C, Zenin O, Ženiš T, Zinonos Z, Zenz S, Zerwas D, Zevi della Porta G, Zhan Z, Zhang D, Zhang H, Zhang J, Zhang X, Zhang Z, Zhao L, Zhao T, Zhao Z, Zhemchugov A, Zhong J, Zhou B, Zhou N, Zhou Y, Zhu CG, Zhu H, Zhu J, Zhu Y, Zhuang X, Zhuravlov V, Zieminska D, Zimin NI, Zimmermann R, Zimmermann S, Zimmermann S, Ziolkowski M, Zitoun R, Živković L, Zmouchko VV, Zobernig G, Zoccoli A, zur Nedden M, Zutshi V, Zwalinski L. A search for [Formula: see text] resonances with the ATLAS detector in 2.05 fb-1 of proton-proton collisions at [Formula: see text]

A search for top quark pair resonances in final states containing at least one electron or muon has been performed with the ATLAS experiment at the CERN Large Hadron Collider. The search uses a data sample corresponding to an integrated luminosity of 2.05 fb-1, which was recorded in 2011 at a proton-proton centre-of-mass energy of 7 TeV. No evidence for a resonance is found and limits are set on the production cross-section times branching ratio to [Formula: see text] for narrow and wide resonances. For narrow Z' bosons, the observed 95 % Bayesian credibility level limits range from 9.3 pb to 0.95 pb for masses in the range of mZ'=500 GeV to mZ'=1300 GeV. The corresponding excluded mass region for a leptophobic topcolour Z' boson (Kaluza-Klein gluon excitation in the Randall-Sundrum model) is mZ'<880 GeV ([Formula: see text]).

Manipulating stored images with phase imprinting at low light levels

Coherent manipulation of stored images is performed at low light levels based on enhanced cross-Kerr nonlinearity in a four-level N-type electromagnetically induced transparency (EIT) system. Using intensity masks in the signal pulse, quadratic phase shifts with low nonlinear absorption can be efficiently imprinted on the Fraunhofer diffraction patterns already stored in the EIT system. Fast-Fourier-transform-based numerical simulations clearly demonstrate that the far-field images of the retrieved probe light can be flexibly modulated by applying different signal fields. Our studies could help advance the goals of nonlinear all-optical processing for spatial information coherently stored in EIT systems.

p53 negatively regulates the osteogenic differentiation of vascular smooth muscle cells in mice with chronic kidney disease

Aim

To investigate the osteogenic differentiation of vascular smooth muscle cells (VSMCs) in mice with chronic kidney disease (CKD) and to evaluate the effects of p53 on the osteogenic differentiation of the VSMCs.

Methods

Experimental models of CKD-associated vascular calcification generated by five-sixth (5/6) nephrectomy (Nx) and a high-phosphate (HP) diet were used in p53+/+ and p53–/– mice. Following 5/6 Nx, aortic calcification, markers of osteogenic differentiation, VSMCs and p53 protein in aortic tissues were studied.

Results

Aortic calcification was observed after eight weeks following 5/6 Nx in mice of both genotypes, and expression of the markers of osteogenic differentiation in the VSMCs was increased. These changes were continuously observed up to 12 weeks after 5/6 Nx, and particularly after 5/6 Nx + HP. Compared with p53+/+ mice, aortic calcification in p53–/– mice was more severe (p < 0.001). Expression of the markers of osteogenic differentiation was noticeably increased (p < 0.001), while expression of the marker of VSMCs had decreased (p < 0.001). Statistical analysis demonstrated that the markers of osteogenic differentiation were negatively correlated with p53, and the marker of VSMCs was positively correlated with p53 (p < 0.001).

Conclusion

p53 has the potential to negatively regulate the osteogenic differentiation of VSMCs in CKD mice.

Search for supersymmetry in events with three leptons and missing transverse momentum in √[s]=7 TeV pp collisions with the ATLAS detector

A search for the weak production of charginos and neutralinos decaying to a final state with three leptons (electrons or muons) and missing transverse momentum is presented. The analysis uses 2.06 fb(-1) of √[s]=7 TeV proton-proton collision data delivered by the Large Hadron Collider and recorded with the ATLAS detector. Observations are consistent with standard model expectations in two signal regions that are either depleted or enriched in Z-boson decays. Upper limits at 95% confidence level are set in R-parity conserving phenomenological minimal supersymmetric and simplified models. For the simplified models, degenerate lightest chargino and next-to-lightest neutralino masses up to 300 GeV are excluded for mass differences from the lightest neutralino up to 300 GeV.

Reassessment of HLA-G isoform specificity of MEM-G/9 and 4H84 monoclonal antibodies

Human leukocyte antigen (HLA)-G is a non-classical HLA class I molecule thought to play a key role in maternal-fetal tolerance. Although initial studies suggested that HLA-G expression is restricted to extravillous cytotrophoblasts, expression was subsequently reported in a wide variety of other human tissues and tumor cells. However, consensus as to the validity of these collective findings has proven difficult because the antibodies used to define the temporal and spatial expression patterns of HLA-G remain incompletely characterized. The aim of our study was to reassess two of the most widely used HLA-G antibodies (MEM-G/9 and 4H84) in HLA-G-positive (JEG-3 and HLA-G transduced) and -negative (dermal fibroblast, mesenchymal stem cell, K562, and Jurkat) lines using flow cytometry, immunofluorescence, and western blotting. We found that MEM-G/9 recognized HLA-G3 by flow cytometry, indicating that its epitope is present on the α1 domain of HLA-G. Although 4H84 preferably recognized unfolded HLA-G-free chains, it showed strong non-specificity under certain methodological conditions.

Denis RD, Stahl T, Stahlman J, Stamen R, Stanecka E, Stanek RW, Stanescu C, Stapnes S, Starchenko EA, Stark J, Staroba P, Starovoitov P, Staude A, Stavina P, Stavropoulos G, Steele G, Steinbach P, Steinberg P, Stekl I, Stelzer B, Stelzer HJ, Stelzer-Chilton O, Stenzel H, Stevenson K, Stewart GA, Stillings JA, Stockmanns T, Stockton MC, Stoerig K, Stoicea G, Stonjek S, Strachota P, Stradling AR, Straessner A, Strandberg J, Strandberg S, Strandlie A, Strang M, Strauss E, Strauss M, Strizenec P, Ströhmer R, Strom DM, Strong JA, Stroynowski R, Strube J, Stugu B, Stumer I, Stupak J, Sturm P, Soh DA, Su D, Subramania HS, Sugaya Y, Sugimoto T, Suhr C, Suita K, Suk M, Sulin VV, Sultansoy S, Sumida T, Sun X, Sundermann JE, Suruliz K, Susinno G, Sutton MR, Suzuki Y, Swedish S, Sykora I, Sykora T, Sánchez J, Ta D, Tackmann K, Taffard A, Tafirout R, Taga A, Taiblum N, Takahashi Y, Takai H, Takashima R, Takeda H, Takeshita T, Talby M, Talyshev A, Tamsett MC, Tanaka J, Tanaka R, Tanaka S, Tanaka S, Tani K, Tannoury N, Tapprogge S, Tardif D, Tarem S, Tarrade F, Tartarelli GF, Tas P, Tasevsky M, Tassi E, Tatarkhanov M, Tayalati Y, Taylor C, Taylor FE, Taylor GN, Taylor W, Teixeira Dias Castanheira M, Teixeira-Dias P, Temming KK, Ten Kate H, Teng PK, Terada S, Terashi K, Terron J, Terwort M, Testa M, Teuscher RJ, Tevlin CM, Therhaag J, Theveneaux-Pelzer T, Thioye M, Thoma S, Thomas JP, Thompson EN, Thompson PD, Thompson PD, Thompson RJ, Thompson AS, Thomson E, Thomson M, Thun RP, Tic T, Tikhomirov VO, Tikhonov YA, Timmermans CJWP, Tipton P, Tique Aires Viegas FJ, Tisserant S, Todorov T, Todorova-Nova S, Toggerson B, Tojo J, Tokár S, Tokunaga K, Tokushuku K, Tollefson K, Tomoto M, Tompkins L, Toms K, Tonazzo A, Tonoyan A, Topfel C, Topilin ND, Torchiani I, Torrence E, Torró Pastor E, Toth J, Touchard F, Tovey DR, Traynor D, Trefzger T, Treis J, Tremblet L, Tricoli A, Trigger IM, Trincaz-Duvoid S, Trinh TN, Tripiana MF, Trischuk W, Trivedi A, Trocmé B, Troncon C, Trottier-McDonald M, Trzupek A, Tsarouchas C, Tseng JCL, Tsiakiris M, Tsiareshka PV, Tsionou D, Tsipolitis G, Tsiskaridze V, Tskhadadze EG, Tsukerman II, Tsulaia V, Tsung JW, Tsuno S, Tsybychev D, Tua A, Tuggle JM, Turala M, Turecek D, Turk Cakir I, Turlay E, Turra R, Tuts PM, Twomey MS, Tykhonov A, Tylmad M, Tyndel M, Typaldos D, Tyrvainen H, Tzanakos G, Uchida K, Ueda I, Ueno R, Ugland M, Uhlenbrock M, Uhrmacher M, Ukegawa F, Unal G, Undrus A, Unel G, Unno Y, Urbaniec D, Urkovsky E, Urrejola P, Usai G, Uslenghi M, Vacavant L, Vacek V, Vachon B, Vahsen S, Valderanis C, Valenta J, Valente P, Valentinetti S, Valkar S, Valladolid Gallego E, Vallecorsa S, Valls Ferrer JA, van der Graaf H, van der Kraaij E, Van Der Leeuw R, van der Poel E, van der Ster D, Van Eijk B, van Eldik N, van Gemmeren P, van Vulpen I, Vandelli W, Vaniachine A, Vankov P, Vannucci F, Vari R, Varnes EW, Varouchas D, Vartapetian A, Varvell KE, Vassilakopoulos VI, Vazeille F, Vegni G, Veillet JJ, Veloso F, Veness R, Veneziano S, Ventura A, Ventura D, Venturi M, Venturi N, Vercesi V, Verducci M, Verkerke W, Vermeulen JC, Vest A, Vetterli MC, Vichou I, Vickey T, Viehhauser GHA, Viel S, Villa M, Villani EG, Villaplana Perez M, Vilucchi E, Vincter MG, Vinek E, Vinogradov VB, Virchaux M, Viret S, Virzi J, Vitale A, Vitells O, Viti M, Vivarelli I, Vives Vaque F, Vlachos S, Vlasak M, Vlasov N, Vogel A, Vokac P, Volpi G, Volpi M, Volpini G, von der Schmitt H, von Loeben J, von Radziewski H, von Toerne E, Vorobel V, Vorwerk V, Vos M, Voss R, Voss TT, Vossebeld JH, Vovenko AS, Vranjes N, Vranjes Milosavljevic M, Vrba V, Vreeswijk M, Vu Anh T, Vuillermet R, Vukotic I, Wagner W, Wagner P, Wahlen H, Wakabayashi J, Walbersloh J, Walch S, Walder J, Walker R, Walkowiak W, Wall R, Waller P, Wang C, Wang H, Wang J, Wang J, Wang R, Wang SM, Warburton A, Ward CP, Warsinsky M, Wastie R, Watkins PM, Watson AT, Watson MF, Watts G, Watts S, Waugh AT, Waugh BM, Weber J, Weber M, Weber MS, Weber P, Weidberg AR, Weigell P, Weingarten J, Weiser C, Wellenstein H, Wells PS, Wen M, Wenaus T, Wendler S, Weng Z, Wengler T, Wenig S, Wermes N, Werner M, Werner P, Werth M, Werthenbach U, Wessels M, Whalen K, Wheeler-Ellis SJ, White A, White MJ, White S, Whitehead SR, Whiteson D, Whittington D, Wicek F, Wicke D, Wickens FJ, Wiedenmann W, Wielers M, Wienemann P, Wiik-Fuchs LAM, Wijeratne PA, Wildauer A, Wildt MA, Wilhelm I, Wilkens HG, Will JZ, Williams E, Williams HH, Willis W, Willocq S, Wilson JA, Wilson MG, Wilson A, Wingerter-Seez I, Winkelmann S, Winklmeier F, Wittgen M, Wolter MW, Wolters H, Wooden G, Wosiek BK, Wotschack J, Woudstra MJ, Wraight K, Wright C, Wright D, Wrona B, Wu SL, Wu X, Wu Y, Wulf E, Wynne BM, Xaplanteris L, Xella S, Xie S, Xu C, Xu D, Yabsley B, Yamada M, Yamamoto A, Yamamoto K, Yamamoto S, Yamamura T, Yamaoka J, Yamazaki T, Yamazaki Y, Yan Z, Yang H, Yang UK, Yang Y, Yang Z, Yanush S, Yao WM, Yao Y, Yasu Y, Ybeles Smit GV, Ye J, Ye S, Yilmaz M, Yoosoofmiya R, Yorita K, Yoshida R, Young C, Youssef S, Yu D, Yu J, Yu J, Yuan L, Yurkewicz A, Zaidan R, Zaitsev AM, Zajacova Z, Zalite YK, Zanello L, Zarzhitsky P, Zaytsev A, Zeitnitz C, Zeller M, Zema PF, Zemla A, Zendler C, Zenin AV, Zenin O, Ženiš T, Zinonos Z, Zenz S, Zerwas D, Zevi della Porta G, Zhan Z, Zhang D, Zhang H, Zhang J, Zhang Q, Zhang X, Zhang Z, Zhao L, Zhao T, Zhao Z, Zhemchugov A, Zhong J, Zhou B, Zhou N, Zhou Y, Zhu CG, Zhu H, Zhu Y, Zhuang X, Zhuravlov V, Zieminska D, Zilka B, Zimmermann R, Zimmermann S, Zimmermann S, Ziolkowski M, Zitoun R, Živković L, Zmouchko VV, Zobernig G, Zoccoli A, Zolnierowski Y, Zsenei A, zur Nedden M, Zutshi V, Zwalinski L. Search for lepton flavour violation in the eμ continuum with the ATLAS detector in [Formula: see text]pp collisions at the LHC

This paper presents a search for the t-channel exchange of an R-parity violating scalar top quark ([Formula: see text]) in the e±μ∓ continuum using 2.1 fb-1 of data collected by the ATLAS detector in [Formula: see text]pp collisions at the Large Hadron Collider. Data are found to be consistent with the expectation from the Standard Model backgrounds. Limits on R-parity-violating couplings at 95 % C.L. are calculated as a function of the scalar top mass ([Formula: see text]). The upper limits on the production cross section for pp→eμX, through the t-channel exchange of a scalar top quark, ranges from 170 fb for [Formula: see text] to 30 fb for [Formula: see text].

Myotonia congenita with strabismus in a large family with a mutation in the SCN4A gene

BACKGROUND/AIMS

To determine the genetic basis of myotonia congenita (MC) and strabismus in a large Caucasian family.

METHODS

Seven patients making up four generations of a family with MC and strabismus were recruited. All patients had at least one standard ophthalmic examination, including best-corrected visual acuity, refraction, and ocular motility measurements. CLCN1 and SCN4A genes were sequenced and analysed for mutations.

RESULTS

Five out of the seven family members were diagnosed with MC by clinical history and electromyography. Ophthalmic history and exam revealed eyelid myotonia and strabismus. All patients with MC were diagnosed with strabismus between the ages of 3 and 6 and required surgical restoration of ocular alignment. Sequencing results revealed a c. 1333G>A; p. Val445Met mutation in the SCN4A gene.

CONCLUSION

There are few reports describing eyelid myotonia and strabismus in patients diagnosed with MC. We found significant ocular involvement in a family with a mutation in SCN4A. Future studies may confirm that MC with significant ocular involvement can be used to direct genetic analysis.

SU-E-T-295: Factors Affecting Accuracy in Proton Therapy

PURPOSE

To examine the various processes involved and to assess their effects on the accuracy in proton therapy.

METHODS

Proton therapy involved several processes: (1) Beam commissioning. (2) CT scan of patient. (3) Contouring. (4) Treatment planning. (5) Output factor measurements for each field. (6) Patient setup verification with image guidance. (7) Dose delivery. (8) Neutron dose and proton RBE at the distal edge. Within each step, there are several sub-processes that each may contribute to the uncertainty in the treatment. By analyzing each of the subprocesseswithin each process, based on measurements or published data, we estimated a % uncertainty to each sub-process and/or a distance uncertainty (in millimeter) on the proton range. A total uncertainty in proton therapy is estimated.

RESULTS

The uncertainties assessed for the various processes are : (1) ±1.5%; (4) ±3.0%, and 1-3mm; (5) ±2.0%; (6) ±2 mm; (7) ±2.0%, ±2mm. The uncertainties in (2) CT, (3) contouring and neutron dose in (8) strongly depend on the location and type of the tumor. On the other hand, the proton RBE at the distal edge in (9) is still debatable and may affect the dose uncertainty from 0-20% depending on which value we want to accept. Thus the overall uncertainty in proton therapy is at least ±4.5% and ±4 mm (by adding the various uncertainties in quadrature), without consideration of processes (2), (3) and (8), and the RBE effect.

CONCLUSIONS

Due to the complexity in proton therapy and the various factors that may affect the accuracy in proton therapy, it is far more complicated to assess the accuracy in proton therapy. Our preliminary study showed that the accuracy in proton therapy is at least ± 4.5% in dose delivered to a tumor with an uncertainty of ±4mm to the distal edge of the SOBP.